PASylation® is a superior alternative to PEGylation which enables second generation biopharmaceuticals with extended plasma half-life and enhanced action. XL-protein’s technology allows a less frequent and lower dosing together with better tolerability, thus making treatment cheaper and supporting patient compliance and safety.
With its strong proprietary technology position, including a broad basis of preclinical data, XL-protein focuses at the preclinical as well clinical development of PASylated proteins in several disease areas. To uncover the full potential of the PASylation technology XL-protein offers licensing opportunities on several levels.
News and Publications
Bavarian Research Foundation supports the development of an immunosuppressive PASylated antibody fragment to support cardiac xenotransplantation
28. September 2022
Rentschler Biopharma and XL-protein demonstrate efficient production of a hyperactive PASylated DNase I with extended half-life
26. October 2021